A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Официальное название

A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)

Обзор

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Вмешательства

• Препарат CHS-114
  Solution for infusion
• Препарат Toripalimab
  Solution for infusion
• Препарат 5 Fluorouracil
  Solution for infusion
• Препарат Cisplatin
  Solution for infusion

Первичные конечные точки

• Number of Participants With Treatment-emergent Adverse Events (TEAEs) [Срок оценки: From first dose of study drug until 90 days after the last dose of study drug (up to approximately 2.25 years)]

Вторичные конечные точки (9)

• Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Investigator Assessment [Срок оценки: Up to approximately 2.25 years]
• Duration of Response (DOR) Per RECIST v1.1 Based on Investigator Assessment [Срок оценки: Up to approximately 2.25 years]
• Disease Control Rate (DCR) Per RECIST v1.1 Based on Investigator Assessment [Срок оценки: Up to approximately 2.25 years]
• Progression-free Survival (PFS) Per RECIST v1.1 Based on Investigator Assessment [Срок оценки: Up to approximately 2.25 years]
• Landmark PFS Rates [Срок оценки: Months 6, 9, and 12]
• Maximum Observed Serum Concentration (Cmax) of CHS-114 [Срок оценки: Up to approximately 2.25 years (pre-infusion and up to 336 hours post-infusion)]
• Time to Reach Cmax (Tmax) of CHS-114 [Срок оценки: Up to approximately 2.25 years (pre-infusion and up to 336 hours post-infusion)]
• Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of CHS-114 [Срок оценки: Up to approximately 2.25 years (pre-infusion and up to 336 hours post-infusion)]
• Number of Participants With Anti-drug Antibodies (ADAs) [Срок оценки: Up to approximately 2.25 years]

Критерии участия

Критерии включения

• At least 1 measurable lesion based on RECIST v1.1 as determined by the Investigator.
• Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgement.

Cohort A (2L Gastric, Gastro-esophageal-junction \[GEJ\], Esophageal Adenocarcinoma \[EAC\]) Specific Inclusion Criteria:

• Histologically or cytologically documented unresectable, locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma that is human epidermal growth factor receptor 2 (HER2) - negative and microsatellite stable (MSS)/proficient mismatch repair (pMMR).
• Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet with or without anti-programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1)-directed therapy (that is, in the second line setting).
• Consent to provide tumor tissue samples (baseline and on-treatment) is required for enrollment.

Cohort B (2L Esophageal Squamous Cell Carcinoma \[ESCC\]) - Specific Inclusion Criteria:

• Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
• Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel with or without anti-PD-1/PD-L1-directed therapy or anti-CTLA-4 and anti-PD-1/PD-L1-directed combination therapy.
• Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
• Consent to provide archival tumor tissue sample (baseline) is required for enrolment.

Cohort C (1L Esophageal Squamous Cell Carcinoma \[ESCC\]) - Specific Inclusion Criteria:

• Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
• Consent to provide baseline tumor tissue is required.
• Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
• Calculated creatinine clearance ≥60 mL/min.

Cohort D, Arms D1 and D2 (4L+ Colorectal Carcinoma \[CRC\]) - Specific Inclusion Criteria:

• Histologically and/or cytologically documented unresectable advanced or metastatic colorectal adenocarcinoma. RAS, BRAF, and microsatellite instability/mismatch repair status for each participant must be documented, according to country level guidelines.
• Participants who have no available therapies with a proven clinical benefit available in the participant's country per investigator. These therapies include the following: fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, anti-VEGF biological therapy (eg, bevacizumab, aflibercept, ramucirumab), an anti-EGFR therapy (eg, cetuximab, panitumumab) if RAS wildtype unless right-sided, either trifluridine/tipiracil, fruqintinib or regorafenib, and a BRAF inhibitor (ie, encorafenib) in BRAF V600E mutant).
• Participants who received oxaliplatin in the adjuvant setting and developed metastatic disease during or within 6 months of completing adjuvant therapy are considered eligible without receiving oxalipatin-based therapy in the metastatic setting.
• Consent to provide baseline tumor tissue sample is required for enrolment.

Критерии исключения

• History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
• Symptomatic or untreated central nervous system metastases, including leptomeningeal metastases, requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids.
• Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.
• Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody.
• History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody (mAb) therapy or any excipient in the study treatment.
• Active uncontrolled bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
• Any condition that, in the opinion of the Investigator or Sponsor, would interfere with the interpretation of study results.

Cohort A (2L Gastric, Gastro-esophageal-junction \[GEJ\], Esophageal Adenocarcinoma \[EAC\]) Specific Exclusion Criteria:

• Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
• Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).

Cohort B (2L Esophageal Squamous Cell Carcinoma \[ESCC\]) - Specific Exclusion Criteria:

• Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
• Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).

Cohort C (1L Esophageal Squamous Cell Carcinoma \[ESCC\]) - Specific Exclusion Criteria:

• Received ≥ 1 prior systemic anticancer therapies for advanced or metastatic disease.
• Participants who progressed during or within 6 months following the last dose of neoadjuvant, or perioperative therapy with curative intent.
• Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
• Known dihydropyrimidine dehydrogenase deficiency or thymidine synthase gene polymorphism predisposing the participant to 5-FU toxicity.
• Known allergies to 5-FU or cisplatin.

Note: Other protocol-specified inclusion/exclusion criteria apply.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 20 центров

• The University of Arizona Cancer Center — Tucson
• City of Hope — Duarte
• University of Colorado - Aurora Cancer Center — Aurora
• Winship Cancer Center - Emory University — Atlanta
• Ochsner Health — New Orleans
• Henry Ford Health System — Detroit
• Comprehensive Cancer Center of Nevada — Las Vegas
• Christus St Vincent Regional Medical Center — Santa Fe
• … и ещё 12 центров

Тайвань · 10 центров

• Changhua Christian Hospital — Chang-hua
• E-Da Cancer Hospital — Kaohsiung City
• Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City
• Taichung Veterans General Hospital — Taichung
• China Medical University Hospital — Taichung
• National Cheng Kung University Hospital — Tainan
• Chi Mei Hospital — Tainan
• National Taiwan University Hospital — Taipei
• … и ещё 2 центра

Публикации

• Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 4;25(5):685-700. doi: 10.1158/1535-7163.MCT-25-0367. PMID 41423415

Идентификаторы

NCT: NCT06657144 · CHS-114-102

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗